Value of contrast-enhanced ultrasound combined with miR-599 level for prognostic evaluation of primary hepatic carcinoma treated with TACE(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2024年第4期
- Page:
- 439-443
- Research Field:
- 医学影像物理
- Publishing date:
Info
- Title:
- Value of contrast-enhanced ultrasound combined with miR-599 level for prognostic evaluation of primary hepatic carcinoma treated with TACE
- Author(s):
- XIAO Yali; LI Conghui
- Department of Ultrasound, Affiliated Hospital of Xiangnan University, Chenzhou 423000, China
- Keywords:
- Keywords: primary hepatic carcinoma transcatheter arterial chemoembolization contrast-enhanced ultrasound microRNA-599 therapeutic efficacy
- PACS:
- R735.7
- DOI:
- DOI:10.3969/j.issn.1005-202X.2024.04.007
- Abstract:
- Abstract: Objective To explore the value of contrast-enhanced ultrasound (CEUS) combined with serum microRNA-599 (miR-599) in evaluating the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) in primary hepatic carcinoma (PHC). Methods A retrospective study was conducted on 80 PHC patients receiving TACE. According to response evaluation criteria in solid tumors (RECIST), the patients were divided into effective group (n=54) and ineffective group (n=26). CEUS was used to obtain the tumor lesion inactivation rate on the 7th day, 14th day, 1st month, and 2nd month after TACE and the serum miR-599 level was measured before TACE and on the 7th day, 14th day, 1st month, and 2nd month after TACE. The results of digital subtraction angiography at the 2nd month after TACE were taken as the gold standard to assess the value of CEUS in evaluation of therapeutic efficacy. The relationship between serum miR-599 and TACE outcome in PHC was analyzed using univariate analysis and multivariate Logistic regression model. Results The evaluation at 2 months after TACE showed that among 80 PHC patients treated with TACE, there were 9 cases of complete response, 45 of partial response, 22 of stable disease, and 4 of progressive disease. The differences in age, body mass index, TACE frequency, Child-pugh grade, and HBsAg result between effective group and ineffective group were trivial (P>0.05) while the two groups differed significantly in preoperative alpha-fetoprotein level, number of lesions, maximum lesion diameter, pathological staging, and whether to use Sofilanide (P<0.05). The lesion inactivation rates at the 1st and 2nd months after TACE were 66.67% and 94.44% in effective group, significantly higher than those in ineffective group (P<0.05). The serum miR-599 levels were significantly lower in ineffective group than in effective group preoperatively, and 7 days, 14 days, 1 month, 2 month postoperatively (P<0.05). The results of Logistic regression model showed that preoperative low miR-599 level, preoperative AFP ≥ 400 μg/L, lesion diameter ≥ 5.0 cm, and pathological staging of stage IIIA were independent risk factors for poor efficacy of TACE in PHC (P<0.05). Sofilanib could improve the efficacy of TACE in treating PHC (P<0.05). Conclusion For PHC patients undergoing TACE, the dynamic observation of lesion changes using CEUS can accurately evaluate the therapeutic effect in clinic. However, primary tumor patients with lower serum miR-599 level have poor response to TACE. Lesion observation using CEUS can be combined with serum miR-599 measurement to comprehensively evaluate the treatment outcome in PHC patients.
Last Update: 2024-04-25